Sugi Predict

Sugi Predict / Compounds / SCHEMBL885000

SCHEMBL885000

SCHEMBL885000

COc1ccccc1CNC(C)=O

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 1/20 0.71
▸ MTNR1B P49286 1/20 0.71
▸ HPGD P15428 6/20 0.69
▸ KMT2A Q03164 3/20 0.65
▸ MEN1 O00255 2/20 0.65
▸ HTT P42858 2/20 0.65
▸ ALDH1A1 P00352 2/20 0.65
▸ NPC1 O15118 2/20 0.65
▸ RAB9A P51151 2/20 0.65
▸ NPSR1 Q6W5P4 1/20 0.65
▸ HDAC1 Q13547 1/20 0.63
▸ GAA P10253 1/20 0.61
▸ KDM4E B2RXH2 1/20 0.61
▸ RCE1 Q9Y256 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ TSHR P16473 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10163441 0.86 HPGD (0.65) MTNR1AMTNR1BHPGDKMT2AMEN1
SCHEMBL2938380 0.86 KMT2A (0.69) HPGDKMT2AMEN1HTTALDH1A1
SCHEMBL13434069 0.86 HPGD (0.69) HPGDKMT2AMEN1HTTALDH1A1
SCHEMBL25189340 0.85 HPGD (0.68) HPGDKMT2AMEN1HTTALDH1A1
SCHEMBL7495080 0.85 ROCK2 (0.59) MTNR1AMTNR1BHPGDKMT2AMEN1
SCHEMBL1520822 0.84 NPSR1 (0.68) HPGDKMT2AMEN1HTTALDH1A1
SCHEMBL8477018 0.83 HPGD (0.61) MTNR1AMTNR1BHPGDKMT2AMEN1
SCHEMBL5724959 0.83 LMNA (0.59) HPGDKMT2AMEN1HTTALDH1A1
SCHEMBL1010724 0.83 MTNR1A (1.00) MTNR1AMTNR1BHPGD
SCHEMBL14670856 0.83 HPGD (0.70) HPGDKMT2AMEN1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148537-B2 Substituted acetophenones useful as PDE4 inhibitors LEO PHARMA A/S (DK) 2012-04-03 — — US claimed
EP-2125736-B1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA AS (DK) 2011-03-30 — — EP claimed
US-20100035908-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA (DK) 2010-02-11 — — US claimed
EP-2125736-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS Leo Pharma A/S (DK) 2009-12-02 — — EP claimed
WO-2008077404-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA A/S (DK) 2008-07-03 — — WO claimed
EP-1730141-A1 COMPOUNDS FOR THE TREATMENT OF DISEASES Pfizer Limited (GB) 2006-12-13 — — EP claimed
EP-1708992-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES Pfizer Limited (GB) 2006-10-11 — — EP claimed
WO-2005092887-A1 COMPOUNDS FOR THE TREATMENT OF DISEASES PFIZER LIMITED (GB) 2005-10-06 — — WO claimed
WO-2005080324-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES PFIZER LIMITED (GB) 2005-09-01 — — WO claimed
US-20230174540-A1 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives GRUENENTHAL GMBH (DE) 2023-06-08 — — US disclosed
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 — — US disclosed
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 — — US disclosed
WO-2020061255-A1 ACTIVATING PYRUVATE KINASE R FORMA THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-10-29 — — US disclosed
WO-2005092887-A1 COMPOUNDS FOR THE TREATMENT OF DISEASES PFIZER LIMITED (GB) 2005-10-06 — — WO disclosed
WO-2005080324-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES PFIZER LIMITED (GB) 2005-09-01 — — WO disclosed
WO-2004100950-A1 ‘(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)-PROPYL!PHENYL DERIVATIVES AS BETA2 AGONISTS PFIZER LIMITED (GB) 2004-11-25 — — WO disclosed
EP-0818439-B1 Imide derivatives NISSHIN FLOUR MILLING CO (JP) 1999-10-13 — — EP disclosed
US-5847123-A Imide derivatives for inhibiting the production of interleukin-1β and the production of tumor necrosis factor α NISSHIN FLOUR MILLING CO., LTD. (JP) 1998-12-08 — — US disclosed
EP-0818439-A2 Imide derivatives NISSHIN FLOUR MILLING CO., LTD. (JP) 1998-01-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 MTNR1A 823/4885MTNR1B 815/4885HPGD 3679/4885
US-20100035908-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS PDE4A, PDE4B, PDE3B MTNR1A 1555/4885MTNR1B 1080/4885HPGD 194/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 MTNR1A 773/4885MTNR1B 747/4885HPGD 3780/4885
US-20230174540-A1 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, PKD2 MTNR1A 419/4885MTNR1B 478/4885HPGD 946/4885
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 MTNR1A 823/4885MTNR1B 815/4885HPGD 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.